SCM
Sio Capital Management Portfolio holdings
AUM
$249M
This Quarter Return
-18.78%
1 Year Return
+117.71%
3 Year Return
+238.99%
5 Year Return
+411.91%
10 Year Return
+912.87%
AUM
$261M
AUM Growth
+$261M
(+11%)
Cap. Flow
+$63.7M
Cap. Flow
% of AUM
24.47%
Top 10 Holdings %
Top 10 Hldgs %
37.23%
Holding
89
New
29
Increased
20
Reduced
14
Closed
14
Top Buys
| 1 |
Cencora
COR
|
$9.97M |
| 2 |
CVS Health
CVS
|
$9.49M |
| 3 |
Medtronic
MDT
|
$8.72M |
| 4 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
$8.2M |
| 5 |
Novo Nordisk
NVO
|
$6.79M |
Top Sells
| 1 |
GSK
GSK
|
$14.6M |
| 2 |
AET
Aetna Inc
AET
|
$12.3M |
| 3 |
Kura Oncology
KURA
|
$8.19M |
| 4 |
Biogen
BIIB
|
$6.82M |
| 5 |
Elevance Health
ELV
|
$6.8M |
Sector Composition
| 1 | Healthcare | 95.45% |
| 2 | Technology | 0.48% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Medtronic
MDT
$119B
| $11.9M | 4.34% | 131,115 +95,919 | +273% | +$8.72M |
|
2
Sanofi
SNY
$121B
| $11.7M | 4.24% | 268,388 +2,000 | +0.8% | +$86.8K |
|
3
Alnylam Pharmaceuticals
ALNY
$58.5B
| $11.3M | 4.11% | 154,637 +50,461 | +48% | +$3.68M |
|
|
4
Cencora
COR
$56.5B
| $9.97M | 3.63% | +133,934 | New | +$9.97M |
|
5
Cigna
CI
$80.3B
| $9.92M | 3.61% | 52,216 -15,233 | -23% | -$2.89M |
|
|
6
CVS Health
CVS
$92.8B
| $9.49M | 3.46% | +144,777 | New | +$9.49M |
|
7
Cardinal Health
CAH
$35.5B
| $9.32M | 3.4% | 209,009 +147,005 | +237% | +$6.56M |
|
8
HCA Healthcare
HCA
$94.5B
| $8.47M | 3.08% | 68,039 -15,783 | -19% | -$1.96M |
|
|
GWPH
9
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $8.2M | 2.99% | +84,186 | New | +$8.2M |
|
|
10
Novo Nordisk
NVO
$251B
| $6.79M | 2.47% | +147,378 | New | +$6.79M |
|
|
CELG
11
DELISTED
Celgene Corp
CELG
| $6.56M | 2.39% | +102,390 | New | +$6.56M |
|
12
MEI Pharma
MEIP
$160M
| $6.27M | 2.28% | 2,373,841 +70,196 | +3% | +$185K |
|
13
Gilead Sciences
GILD
$140B
| $6.04M | 2.2% | +96,480 | New | +$6.04M |
|
|
UROV
14
DELISTED
Urovant Sciences Ltd.
UROV
| $5.32M | 1.94% | 807,860 +216,406 | +37% | +$1.43M |
|
15
McKesson
MCK
$85.4B
| $5.14M | 1.87% | +46,530 | New | +$5.14M |
|
16
Viatris
VTRS
$12.3B
| $5.13M | 1.87% | +187,175 | New | +$5.13M |
|
17
Premier
PINC
$2.14B
| $5.02M | 1.83% | 134,412 -10,000 | -7% | -$373K |
|
18
Rigel Pharmaceuticals
RIGL
$697M
| $5.02M | 1.83% | 2,180,546 +337,045 | +18% | +$775K |
|
19
Molina Healthcare
MOH
$9.8B
| $4.98M | 1.81% | +42,869 | New | +$4.98M |
|
20
Neurocrine Biosciences
NBIX
$13.8B
| $4.93M | 1.79% | +69,000 | New | +$4.93M |
|
21
Viking Therapeutics
VKTX
$3.04B
| $4.87M | 1.78% | 637,046 +423,794 | +199% | +$3.24M |
|
22
Bionano Genomics
BNGO
$17.6M
| $4.85M | 1.77% | 1,436,461 -4,396 | -0.3% | -$14.9K |
|
|
DRNA
23
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $4.74M | 1.73% | +443,409 | New | +$4.74M |
|
24
Humana
HUM
$36.5B
| $4.67M | 1.7% | 16,317 -3,737 | -19% | -$1.07M |
|
25
Emergent Biosolutions
EBS
$443M
| $4.37M | 1.59% | 73,793 +31,994 | +77% | +$1.9M |
|